Bayer Aktiengesellschaft

Wolfgang Bruns

Eugen Schnabel

Gerd Reinhardt

Werner Schroder

Ernst-August Auerswald

Dietrich Horlein

Michael Kotick

Ronald Frank

Hans Fritz

Helmut Blocker

John Collins

Friedhelm Maywald

Peptides having essentially the sequence of bovine pancreatic trypsin inhibitor (aprotinin) wherein one or more of the amino acids at positions 15, 16, 17, 18, 34, 39 and 52 are replaced by any naturally occurring amino acid produced by recombinant DNA technology, process, expression vector and recominant host therefor and pharmaceutical use thereof. Such peptides being useful as therapeutic agents in diseases connected with the presence of excessive amounts of proteinases.

Variants of bovine pancreatic trypsin inhibitor produced by recombinant

The present invention relates to a peptide having essentially the amino acid sequence of pancreatic secretory trypsin inhibitor (PSTI). The present invention also relates to variants of such peptide wherein one or more of the amino acids in the original sequence are replaced by other amino acids. These peptides show an advantageously modified specificity in their inhibotory action. A method of preparation of the peptides and their pharmaceutical use is also described.

Pancreatic secretory tryspin inhibitor and variants thereof produced by

Variants of bovine pancreatic trypsin inhibitor and pharmaceutical use

Microbially produced aprotinin and aprotinin homologs used for treating patients suffering from an excess release of pancreatic elastase, serum elastase or leukocyte elastase.

Homologs of aprotinin produced from a recombinant host, process,

Homologs of aprotinin produced from a recombinant host, process

Growing community of inventors

Wuppertal, Germany

Wolfgang Bruns